ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

Neuroendocrinology

Volumn 91, Issue 4, 2010, Pages 341-350

  Kos Kudła, Beata ^a   O'Toole, Dermot ^b   Falconi, Massimo ^c   Gross, David ^d   Klöppel, Günther ^e   Sundin, Anders ^f   Ramage, John ^g   Öberg, Kjell ^f   Wiedenmann, Bertram ^h   Komminoth, Paul ⁱ   Van Custem, Eric ^j   Mallath, Mohandes ^k   Papotti, Mauro ^l   Caplin, Martyn ^m  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY OF VERONA   (Italy)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF KIEL   (Germany)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ Kantonsspital Baden   (Switzerland)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k TATA MEMORIAL HOSPITAL   (India)

^l UNIVERSITY OF TURIN   (Italy)

^m ROYAL FREE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYINDOLEACETIC ACID; 6 FLUORODOPA F 18; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHROMOGRANIN A; DEPREOTIDE TC 99M; GALLIUM 68; HORMONE; HYPOPHYSIS HORMONE; INTERFERON; LUTETIUM 177; PARATHYROID HORMONE; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; YTTRIUM 90;

BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; COUGHING; ECTOPIC HORMONE PRODUCTION; FOLLOW UP; FRACTURE; GASTRINOMA; GENETIC PREDISPOSITION; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; LABORATORY TEST; LUNG METASTASIS; MOOD DISORDER; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL REHYDRATION THERAPY; PAIN; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SOCIAL ATTITUDE; STERNOTOMY; SURVIVAL RATE; THORACOTOMY; THORAX RADIOGRAPHY; ZOLLINGER ELLISON SYNDROME; BONE NEOPLASMS; DIGESTIVE SYSTEM TUMOR; LUNG NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE; SECONDARY;

BONE NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS;

EID: 77954658554     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000287255     Document Type: Conference Paper

References (49)

1. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM: Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-2664.
2. Hadi S, Zhang L, Hird A, de Sa E, Chow E: Validation of symptom clusters in patients with metastatic bone pain. Curr Oncol 2008; 15: 211-218.
3. Zuetenhorst JM, Hoefnageli CA, Boot H, Valdés Olmos RA, Taal BG: Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002; 23: 735-741.
4. Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, de Vries EG, Willemse PH: Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 2003; 44: 184-191.
5. Hlatky R, Suki D, Sawaya R: Carcinoid metastasis to the brain. Cancer 2004; 101: 2605-2613.
6. Lombard-Bohas C, Mitry E, O'Toole D, Louvet C, Pillon D, Cadiot G, Borson-Chazot F, Aparicio T, Ducreux M, Lecomte T, Etienne PL, Cacheux W, Legoux JL, Seitz JF, Ruszniewski P, Chayvialle JA, Rougier P, FFCDANGH-GERCOR: Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 2009; 89: 217-222.
7. Zuetenhorst JM, Taal BG: Metastatic carcinoid tumors: a clinical review. Oncologist 2005; 10: 123-131.
8. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8: 685-690.
9. Ross EM, Roberts WC: The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med 1985; 79: 339-354.
10. Taal BG, Visser O: Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004; 80: 3-7.
11. Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS: Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics 2006; 26: 41-58.
12. Khan JH, McElhinney DB, Rahman SB, George TI, Clark OH, Merrick SH: Pulmonary metastases of endocrine origin: the role of surgery. Chest 1998; 114: 526-534.
13. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
14. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM: Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113: 5-21.
15. Scarsbrook AF, Ganeshan A, Statham J, Thakker RV, Weaver A, Talbot D, Boardman P, Bradley KM, Gleeson FV, Phillips RR: Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics 2007; 27: 455-477.
16. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S, Frascati Consensus Conference participants: Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8-19.
17. Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, Kaltsas G, Kelestimur F, Kvols L, Scoazec JY, Garcia MI, Caplin ME, Frascati Consensus Conference participants: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 2008; 87: 31-39. (Pubitemid 350308292)
18. Plöckinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH, Knigge UP, Kulke MH, Pape UF, Frascati Consensus Conference participants: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology 2008; 87: 20-30.
19. Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, Jensen R, Kos-Kuda B, Öberg K, O'Connor JM, Pavel ME, Vullierme MP, Frascati Consensus Conference participants: Poorly differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008; 87: 40-46.
20. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle Fave GF, O'Toole D, Frascati Consensus Conference participants: Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2008; 87: 47-62.
21. Nilsson O, Van Cutsem E, Delle Fave G, Yao JC, Pavel ME, McNicol AM, Sevilla Garcia MI, Knapp WH, Keletimur F, Sauvanet A, Pauwels S, Kwekkeboom DJ, Caplin M, Frascati Consensus Conference participants: Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006; 84: 212-215.
22. Falconi M, Plöckinger U, Kwekkeboom DJ, Manfredi R, Körner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmüller T, Öberg K, Scoazec JY, Frascati Consensus Conference participants: Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 2006; 84: 196-211.
23. Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Wolf O, Bechstein WO, Christ E, Taal BG, Knigge U, Ahlman H, Kwekkeboom DJ, O'Toole D, Frascati Consensus Conference participants: Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology 2006; 84: 165-172.
24. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O'Connor JM, Pauwels S, Kloppel G, Frascati Consensus Conference, European Neuroendocrine Tumor Society: Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182.
25. Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H, Pauwels S, Kwekkeboom DJ, Rindi G, Frascati Consensus Conference, European Neuroendocrine Tumor Society: Well differentiated gastric tumors/carcinomas. Neuroendocrinology 2006; 84: 158-164.
26. De Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D, Frascati Consensus Conference, European Neuroendocrine Tumor Society: Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183-188.
27. O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder W, Hyrdel R, Nikou G, Drenning E, Vullierme M, Caplin M, Jensen R, Eriksson B: Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006; 84: 189-195.
28. Lepage C, Rachet B, Coleman MP: Survival from malignant digestive endocrine tumors in England and Wales: a population-based study. Gastroenterology 2007; 132: 899-904.
29. Mignon M: Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000; 62(suppl 1):51-58.
30. Kos-Kuda B, Bolanowski M, Handkiewicz-Junak D, Jarzab B, Królicki L, Krzakowski M, Kunikowska J, Nasierowska-Guttmejer A, Nowak A, Rydzewska G, Starzyska T, Szawowski A, Round Table Conference participants: Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors). Endokrynol Pol 2008; 59: 41-56. (Pubitemid 351547476)
31. Srirajaskanthan R, McStay M, Toumpanakis C, Meyer T, Caplin ME: Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review. Neuroendocrinology 2009; 89: 48-55.
32. Reubi JC: Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004; 80: 51-56.
33. Amthauer H, Denecke T, Rohlfing T, Ruf J, Böhmig M, Gutberlet M, Plöckinger U, Felix R, Lemke AJ: Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours. Eur Radiol 2005; 15: 1456-1462.
34. Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, Rougier P, Duron F, Bouchard P, Grangé JD, Houry S, Talbot JN: Impact of fluorodihydroxyphenylalanine-( 18 F) PET on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009; 94: 1295-1301.
35. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ: Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18 F-FDG. Cancer 2008; 112: 2447-2455.
36. Debray MP, Geoffroy O, Laissy JP, Lebtahi R, Silbermann-Hoffman O, Henry-Feugeas MC, Cadiot G, Mignon M, Schouman-Claeys E: Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol 2001; 74: 1065-1070.
37. Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, Chosidow D, Faraggi M, Mignon M, Le Guludec D: Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999; 40: 1602-1608.
38. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
39. Rivera MP, Detterbeck F, Mehta AC: Diagnosis of lung cancer: the guidelines. Chest 2003; 123(1 suppl):129S-136S.
40. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning E, de Herder W, Goede A, Caplin M, Oberg M, Reubi J, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 2004; 80: 395-424.
41. Kaltsas G, Besser G, Grossman A: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511.
42. Costa L, Major PP: Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009; 6: 163-174.
43. Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour KA, Miller JI: The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest 2001; 119: 14-18.
44. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB: Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008; 15: 701-720.
45. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP: Radiolabeled somatostatin analog [177 Lu-DOTA0,Tyr 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
46. Chan JA, Kulke MH: Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs 2008; 12: 253-270.
47. Oberg K, Eriksson B: Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 265-276.
48. Gkialas I, Iordanidou L, Galanakis I, Giannopoulos S: The use of radioisotopes for palliation of metastatic bone pain. J BUON 2008; 13: 177-183.
49. Fairchild A, Chow E: Role of radiation therapy and radiopharmaceuticals in bone metastases. Curr Opin Support Palliat Care 2007; 1: 169-173.